Jynarque

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Jynarque helps slow worsening of kidney function in patients with ADPKD, a genetic disease in which cysts form in the kidney. Do not drink grapefruit juice during treatment.

Jynarque Overview

Reviewed: June 19, 2018
Updated: 

Jynarque is a prescription medication used to prevent worsening of kidney function in patients with autosomal dominant polycystic kidney disease (ADPKD) who are at risk for rapid decline. Jynarque belongs to a group of drugs called vasopressin 2 receptor antagonists, which work to block the action of vasopressin and slow the growth of cysts in the kidney.

This medication comes in tablet form and is taken 2 times per day: once upon waking and once 8 hours later.

Common side effects of Jynarque include increased urination, thirst, and dry mouth. Jynarque can also cause drowsiness. Do not drive or operate heavy machinery until you know how Jynarque affects you.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Jynarque Drug Class

Back to Top

Jynarque is part of the drug class:

Jynarque FDA Warning

Back to Top

WARNING: RISK OF SERIOUS LIVER INJURY

Jynarque can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported.

Measure ALT, AST and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity.

Because of the risks of serious liver injury, Jynarque is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the Jynarque REMS Program.